Nonossifying fibromas and fibrous cortical defects are benign, self-healing fibrous defects that occur in the metaphyses of long bones in children and adolescents. Together they represent the most common benign lesions of the skeletal system, with an estimated incidence of 30% to 40% in skeletally immature children. 1,2 On radiographs, fibrous cortical defects are small, subperiosteal, intracortical, metaphyseal lesions. Nonossifying fibromas are larger than fibrous cortical defects, occupy an eccentric location in the medullary cavity of long-bone metaphyses, and usually involve, but do not breach, the adjacent cortex. Except for their size and the extent of metaphyseal involvement, nonossifying fibromas and fibrous cortical defects are indistinguishable, sharing a common presentation, histology, and natural history. They may be referred to collectively as metaphyseal fibrous defects. 3 The clinical and radiographic features of metaphyseal fibrous defects are fairly consistent, as is their usual asymptomatic, self-limited natural history. Because of their very typical appearance and presentation, recognizing these lesions and making the definitive diagnosis should not be difficult in most cases. However, patients with these lesions frequently are referred to an orthopaedic oncologist. Awareness of the prevalence and diagnostic features of these lesions should spare children and their families further costly and invasive diagnostic modalities as well as the anxiety associated with the preliminary diagnosis of a "bone tumor."
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History and Etiology
Common, cyst-like, cortical, metaphyseal lesions were first described in 1941 by Sontag and Pyle, 1 who thought the lesions to be cartilaginous in origin. By 1945, Hatcher 3 and Jaffe and Lichtenstein 4 had demonstrated that these lesions are composed of fibrous tissue, giving rise to the term fibrous cortical defects. Jaffe and Lichtenstein 4 noted that, in some cases, the lesion seemed to persist, proliferate, and extend into the adjacent medullary cavity. They considered these large lesions that now occupied the medullary cavity to be neoplasms evolving from fibrous cortical defects, and they termed them nonosteogenic or nonossifying fibromas. In 1955, Caffey 2 suggested that the histology of the fibrous cortical defects described by Hatcher and the nonosteogenic fibromas described by Jaffe and Lichtenstein were identical, despite their differing radiographic appearance. Caffey did not believe that fibrous cortical defects evolve into larger, intramedullary nonossifying fibromas and stated that "this phenomenon of intramedullary extension and overgrowth of the smaller cortical defects has never been seen in the scores of cases we have observed serially; similarly expansion to great size was not reported in the large series of Sontag and Pyle, and of Hatcher." 2 The etiology of fibrous cortical defects remains unknown. Jaffe and Lichtenstein 4 considered them to be benign tumors that arise from mature marrow connective tissue and thought that the essential characteristic of their growth is the complete absence of osseous metaplasia. Hatcher 3 contended that these lesions result from a local disturbance of bone growth originating at the epiphyseal plate and did not think that they represent a true neoplastic process. He thought that the term nonosteogenic or nonossifying was incorrect because these lesions eventually were replaced by bone. Hatcher referred to these lesions collectively as metaphyseal fibrous defects.
The term nonossifying fibroma has remained because it is thought that the lesions themselves do not make bone; rather, they are replaced by bone that fills in from the peripheral rim of normal bone tissue. Mirra 5 has suggested that when a suspected nonossifying fibroma appears to be making bone from within, it must be doing so secondary to a process of fibro-osseous metaplasia. When that occurs, the lesion is more likely to be either fibrous dysplasia or low-to moderate-grade osteosarcoma. 5 
Prevalence
The peak age at the time of diagnosis of nonossifying fibromas and fibrous cortical defects is during the second decade of life. Males are affected more frequently than females (2:1). 1, 2, 5, 6 The lesions are most commonly located in the distal femoral metaphysis, followed by the proximal and distal tibial metaphyses. Although they can occur in the proximal humerus and distal radius, they are much less frequent in the upper extremity. [2] [3] [4] [5] However, most lesions are discovered incidentally, and therefore the age, gender, and site distributions may be confounded by the rates of occurrence and the rationale for radiographic evaluation in children (eg, trauma).
Clinical Presentation and Evaluation
Three-phase bone scans, computed tomography (CT), and magnetic resonance imaging (MRI) are rarely needed to make a diagnosis of fibrous cortical defect or nonossifying fibroma. The diagnosis most often can be made definitively based solely on the patient's history, physical examination, and plain radiographic appearance.
Occasionally, a patient may present with pain and swelling secondary to a stress fracture (Fig. 1) or even a minimally displaced fracture that occurred because of trauma, with the lesion being a stress riser for the origin. However, physical examination of patients with a fibrous cortical defect or nonossifying fibroma usually is normal without abnormal findings, although occasionally there may be tenderness associated with the lesion. The presence of a soft-tissue mass should preclude the diagnosis of a metaphyseal fibrous defect.
Radiographic Features
An understanding of the key radiographic characteristics of these lesions is paramount to diagnosing fibrous cortical defects and nonossifying fibromas (Fig. 2 ). Equally important is knowing which variations of these features indicate other conditions in the differential diagnosis. Fibrous cortical defects are small (usually 1 to 3 cm), round-to-ovoid lesions eccentrically located in the metaphysis and/or the metaphysealdiaphyseal junction (Fig. 1) . They appear as intracortical or juxtacortical radiolucencies with a peripheral rim of sclerosis that does not involve the medullary bone. As with nonossifying fibromas, they are longer than they are wide. 2, 5 Nonossifying fibromas are radiolucent, eccentric, cortically based lesions that involve varying amounts of the adjacent medullary cavity (Fig. 2) . They have distinct, sclerotic margins that are frequently scalloped, with a narrow zone of transition to normal bone. The cortex overlying the lesion is occasionally "expanded" and thinned but remains intact. Prevention of the normal remodeling of the metaphysis as it joins the diaphysis is most likely the cause of this so-called expansion. There is no intralesional matrix mineralization, but nonossifying fibromas can have an internal "bubbly" appearance that is created by thin, white septae resulting from ridging of the cortex (Fig. 2) . The lesion's distance from the epiphyseal plate usually increases with the age of the patient. When they occur in bones with a smaller diameter (eg, the ulna), nonossifying fibromas can occupy the entire metaphysis. 5, [7] [8] [9] 
Pathologic Characteristics
On gross examination of biopsy specimens of both nonossifying fibromas or of fibrous cortical defects, the tissue is fibrous, fleshy, and yellow or tan-brown with variable areas of hemorrhage. Histologically, these lesions are highly cellular, with fibroblastic/ spindle-shaped cells amid stromal tissue in a prominent storiform pattern. The stroma also may contain multinucleated giant cells, foci of xanthomatous reaction with foamy histiocytes, and a substantial amount of hemosiderin pigment in the stromal cells (Fig.  3) . Mitotic figures or cellular dysplasia are uncharacteristic. 4, 5 Depending on the radiographic appearance, the differential diagnosis for fibrous cortical defects includes osteoid osteomas, intracortical abscesses, stress fractures, and intracortical osteosarcoma. The differential diagnosis for nonossifying fibromas includes aneurysmal bone cyst, chondromyxoid fibroma, fibrous dysplasia, and desmoplastic fibroma. 2, 5 Lesions that are eccentrically located in the metaphysis, have an intact cortex and a sclerotic, well-demarcated rim, and do not demonstrate either a Codman's triangle or extraosseous extension should be considered metaph- yseal fibrous defects. This diagnosis precludes further evaluation. If a radiolucent lesion fails to demonstrate these characteristic findings, a definitive diagnosis cannot be determined from plain radiographs (Fig. 4) . If the patient has no symptoms, close observation with serial radiographs is often the most reasonable management. However, referral to an orthopaedic oncologist for further evaluation would be justifiable depending on the treating physician's level of comfort with lesions that differ from the typical radiographic characteristics of metaphyseal fibrous defects.
Additional imaging also may be helpful for lesions that lack the classic radiographic appearance. CT can be used to verify the exact size of the lesion, identify subtle changes in lesion size over time, and determine the presence of cortical integrity or pathologic fracture. MRI will distinguish a lesion with cystic components or provide a more detailed assessment of the local osseous and soft-tissue response to the lesion. There are some variations in the MRI appearance of metaphyseal fibrous defects, as demonstrated in a study of 19 histologically confirmed lesions. 10 All were hypointense on T1-weighted images, but their signal characteristics varied on T2-weighted images, with some having more high-signal regions than others. The authors concluded that signal intensity varied markedly and was dependent on the specific amounts of hypercellular fibrous tissue, hemosiderin, hemorrhage, collagen, foamy histiocytes, and bone trabeculae present in a given lesion 10 ( Figs. 5 and 6 ).
According to Brenner et al 11 and Greyson and Pang, 12 a three-phase bone scan can help differentiate whether a given lesion is active, healing, or inactive based on the intensity of the uptake on the scan. Intense hyperemia and a markedly positive scan suggest a more active process, such as an associated fracture. Mild hyperemia and moderate bone uptake are present during the healing phase. Normal scans are obtained when the lesion is quiescent or has fully healed. However, bone scans should not be routinely ordered for the diagnosis or management of suspected metaphyseal fibrous defects. Ultimately, a biopsy of the lesion may be necessary to provide definitive diagnostic information for nonossifying fibromas that fail to demonstrate classic radiographic features.
Multifocal Nonossifying Fibroma
Most cases of multifocal nonossifying fibroma involve patients with coexistent neurofibromatosis (ie, von Reck- linghausen's disease) [13] [14] [15] [16] [17] [18] or a familial association. 19 Patients with JaffeCampanacci syndrome demonstrate multifocal nonossifying fibromas with extraskeletal congenital anomalies such as café-au-lait spots, mental retardation, hypogonadism, cryptorchidism, ocular anomalies, and/or cardiovascular malformations. 14, 15 Multifocal nonossifying fibromas also can occur in patients without extraskeletal manifestations. Patients may have lesions on both the medial and lateral aspects of the distal femur or proximal tibia as well as on the ipsilateral femur and tibia. In a retrospective review of 900 patients with nonossifying fibromas, 72 of the patients (8%) were found to have more than one lesion, with only 5% of these (3/72) having the diagnosis of an underlying disorder such as neurofibromatosis. 17 This study likely underestimated the incidence of multifocal nonossifying fibromas because the patients were not routinely screened for other lesions with either plain radiography or bone scan.
There is no absolute indication for screening for the presence of multifocal lesions in a patient presenting with a single nonossifying fibroma. Relative indications include a patient with a single lesion and neurofibromatosis or any of the findings associated with Jaffe-Campanacci syndrome, a patient with pathologic fracture, or patient or parent anxiety regarding the presence of multiple lesions. Experience in our institution is that a three-phase bone scan often failed to detect quiescent lesions large enough to lead to pathologic fracture; thus, its usefulness as a screening tool is limited. A limited skeletal survey performed in patients with nonossifying fibroma to rule out multifocal lesions should include anteroposterior radiographs of both tibias, fibulas, femurs, and humeri. These locations account for >90% of all nonossifying fibromas (tibia, 43%; femur, 38%; fibula, 8%; humerus, 5%). 20 Healed or quiescent lesions also are reliably detected on plain radiographs.
Natural History
Most fibrous cortical defects undergo spontaneous regression, usually starting at the end of adolescence. Most disappear by age 20 to 25 years. Because of an accelerated rate of skeletal maturation, regression begins earlier in females. 2, 5 The average time from diagnosis to complete spontaneous regression ranges from 29 to 52 months, with most lesions remaining clinically silent throughout. 1, 2, 21 The regressive phase is characterized by a patchy loss or "fading out" of the lesion radiographically. Trabecular bone growth is noted initially at the periphery of the lesion and then continues to form from the outside in until the bone is reconstituted to a normal state. 3, 5 The natural history of nonossifying fibroma also is one of spontaneous regression. Regression occurs along the same time course as that for fibrous cortical defects: most begin to regress or undergo osseous replacement in the young adult nearing skeletal maturity. Nonossifying fibromas usually take longer to completely resolve than do fibrous cortical defects because of their larger size. 5 Nonossifying fibromas differ clinically from fibrous cortical defects in that they are more likely to become symptomatic before regression, and they may potentially become quite large and lead to a pathologic fracture.
Management
Once they are detected, fibrous cortical defects and small, asymptomatic nonossifying fibromas can be followed with serial radiographs. If the size and appearance of the lesion are unchanged on a repeat radiograph 3 months later, the patient may be followed with serial radiographs every 6 months to 1 year until regression occurs or symptoms develop.
Large nonossifying fibromas that cause pain or swelling can be treated with biopsy, curettage, and autograft/ allograft packing. Similarly, biopsy and subsequent curettage and grafting should be performed in any patient whose lesion has atypical clinical or radiologic features. Finally, as an isolated treatment modality, protected weight bearing with bracing or crutches has limited utility; it does not affect the lesion itself and serves only to further weaken adjacent normal bone through disuse.
Because the risk for malignant transformation essentially is nonexistent, the key concern and indication for radiographic monitoring of nonossifying fibromas is avoidance of pathologic fracture. Pathologic fractures are notably more common in the lower extremities, composing nearly 90% of all fractures with almost 50% occurring in the distal tibia. [22] [23] [24] Despite attempts to assess the risk for pathologic fracture in bone, there is no validated method, and no single model has proved to be accurate enough to warrant widespread clinical use. Arata et al 22 suggested that risk factors for a pathologic fracture were nonossifying fibromas that occupy >50% of the transverse diameter of the bone on both anteroposterior and lateral radiographs and those longer than 33 mm in the weightbearing bones (femur and tibia). Employing the same definition of "large," Easley and Kneisl 24 found that using an absolute size threshold to predict the risk for pathologic fracture was unreliable; they concluded that such criteria should not serve as indications for prophylactic treatment.
Most pathologic fractures through nonossifying fibromas are nondisplaced and can be treated with cast immobilization until the fracture has healed. The patient then should undergo biopsy, curettage, and bone grafting in an effort to reduce the risk for refracture. Infrequently, pathologic fractures through nonossifying fibromas require internal fixation to achieve stability and healing. In general, it is appropriate to manage these fractures with the same principles of care that are applied to nonpathologic fractures at the same location. Intramedullary fixation is not contraindicated. Additionally, the presence of these lesions does not preclude normal fracture healing.
The surgical technique for resection or curettage is relatively straightforward. A longitudinal incision is made directly over the lesion. Care should be taken not to dissect through intermuscular planes or around neurovascular structures. If the suspected nonossifying fibroma is a malignant lesion, violating additional planes and neurovascular structures would contaminate previously uninvolved compartments. Passage into the lesion can be obtained by creating a small cortical window with an osteotome or small, sharp curet. Access to the entire contents of the cavity should be obtained so that ample tissue is available for both frozen and permanent pathologic specimens. For unusually shaped lesions, a standard 30°arthroscope can be placed into the cortical window to aid the visualization and curettage of the lesion.
The choice between the use of autologous bone graft or a substitute usually is based on surgeon preference. Demineralized bone matrix, allograft bone chips, and ceramics all have been used successfully, sparing the patient the morbidity of an autograft harvest.
Summary
Fibrous cortical defects and nonossifying fibromas are common lesions in the general patient population. Evaluation of these lesions typically is limited to the history, physical examination, and radiographic imaging. When a radiolucent lesion fails to demonstrate the classic characteristics of a fibrous cortical defect or nonossifying fibroma, referral to an orthopaedic oncologist is indicated. CT and/or MRI then can be used to better characterize the lesion. Lesions in an asymptomatic patient may justify referral to an orthopaedic oncologist. When evaluation for multiple lesions is indicated, a limited skeletal survey to screen for additional lesions is a safer, less expensive, and more sensitive alternative to three-phase bone scan. These lesions may be followed over time by serial radiographs until regression or onset of symptoms occurs. Biopsy, curettage, and bone grafting are indicated for large, symptomatic lesions that pose a significant threat for impending fracture based on their size and the extent of bone involvement, or for lesions with any characteristics that are atypical for either a fibrous cortical defect or a nonossifying fibroma. Patients presenting with a pathologic fracture are immobilized until healing is evidenced clinically and radiographically, at which time the lesion should be biopsied, curetted, and bonegrafted.
